Dr Liz Dallimore provided MarketOpen with some insights following an FDA clinical hold on the Argenica’s US IND application, and why it doesn’t impact the ongoing Phase 2 trial in Australia.Listen to the full conversation below ⬇️#ASX#AGN#stroke#clinicaltrial
Argenica Therapeutics (ASX: AGN) Managing Director Dr Liz Dallimore provided insights following an FDA clinical hold on the company’s US IND application, and why it doesn’t impact the ongoing Phase 2 trial in Australia.In the video, Liz discusses: How Argenica plans to address the FDA’s request for more data The successful completion of dosing in the Australian Phase 2 trial Her pride in the team for hitting this milestone What investors can expect from the Q3 data readoutDianne Angus | Mark Etherton | Jeannie Joughin PhD, GAICD | Bruno Meloni | Meghan Thomas | Stuart Gribble | Emma Waldon | Adam Edwards | Stewart Walters | Holly Walters | Riley Maring#StrokeTreatment#Biotech#ClinicalTrials#ASX#FDA#Neuroscience#ArgenicaTherapeutics#ARG007#DrugDevelopment#MedTechAustralia
Current Time Duration
Ann: Update on Investigational New Drug Application, page-27
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
71.0¢ |
Change
-0.010(1.39%) |
Mkt cap ! $90.94M | |||
| Open | High | Low | Value | Volume |
| 73.5¢ | 73.5¢ | 70.5¢ | $48.50K | 66.80K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 28542 | 70.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 71.0¢ | 29910 | 1 |
View Market Depth
| Last trade - 15.27pm 20/06/2025 (20 minute delay) ? |
| AGN (ASX) Chart |